The story of a husband and wife who traveled from Melbourne, Australia for treatment of dementia utilizing the revolutionary new treatment invented by the founder of TransBarrier®. Before and after video, testing, and interview with the patient’s wife.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2019 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, Australian patent 758523.

Rapid improvement following anti-TNF treatment at TransBarrier® is seen. The patient is able to recognize his wife for the first time in years within minutes after treatment. Also seen is his improvement in verbal abilities following the local anti-TNF dose.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2019, TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, Australian patent 758523.

Son comments on the immediate difference he saw after the first dose of his father’s anti-TNF treatment. This video documents the unprecendented rapid improvement that may occur after initiation of treatment at TransBarrier®. Includes video both before and after treatment and discussion by the patient’s wife and son.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2019, TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, Australian patent 758523.

A patient with chronic traumatic brain injury discusses his rapid clinical improvement following treatment at TransBarrier® in Los Angeles 45 years after  being struck by a car at age 6. This treatment is available for new patients at TransBarrier®. For further information, please call TransBarrier® in Los Angeles at (310) 479-0107 or at (561) 353-9707 in Boca Raton, Florida.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Husband and wife discuss improvements following local anti-TNF treatment at TransBarrier® in Los Angeles years after stroke. This new patented treatment is available for new patients at the TransBarrier®. For further information, please call the TransBarrier® in Los Angeles at (310) 479-0107. The patented TransBarrier® stroke treatment is also available at TransBarrier® in Boca Raton, Florida; please call (561) 353-9707.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

 

A severe stroke occurred at age 22. Treatment at TransBarrier® in Boca Raton, Florida occurred in September 2011. This video documents some of the clinical improvements noted. This new patented treatment is available for new patients at TransBarrier®. For further information, please call TransBarrier® in Boca Raton, Florida, at (561) 353-9707.

Please see Rapid improvement of chronic stroke deficits…: three consecutive cases. CNS Drugs. 2011 Feb;25(2):145-155.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2011-2019 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, Australian patent 758523.

In this interview, the son of an TransBarrier® patient discusses his father’s response since starting treatment at TransBarrier®. He explains how much this has meant to him and his family.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including Australian patent 758523.

Rapid improvement in post-stroke pain and additional clinical improvements documented following TransBarrier® patented anti-TNF treatment, 17 years after stroke.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.

Six months of sustained clinical improvement nearly five years after stroke following TransBarrier® patented off-label treatment is documented. Improvements in hand and arm function, gait, and walking speed are documented.

Chronic neurological dysfunction produced by stroke and traumatic brain injury has long been thought to be irreversible. A new scientific discovery by TransBarrier®, as documented in the video above, now promises to change current thinking about the potential for recovery of function, even years after the acute event.

Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label.  Please see the Terms of Use. Copyright 2015 TransBarrier®, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.